Mesoblast Ltd

George Gregory’s bulk purchases of Mesoblast shares signal confidence in its biotech pipeline, especially after FDA approval for Ryoncil, and may anchor the stock during volatile clinical milestones.

Insider George Gregory buys 13.5 M Mesoblast shares at $1.48 after FDA green‑light, signaling confidence in DMD therapy and potential upside for risk‑tolerant biotech investors.

Mesoblast insider Krause keeps 287,500 shares and staged option grants, signalling long‑term confidence amid volatile pricing and rising social‑media buzz.

Insider filing reveals Mesoblast’s leadership confidence—options tied to 2030‑2032 milestones may boost the stock if R&D Day succeeds, but risk a bearish outcome if targets miss.